Bronchodilator response not a significant marker of poor asthma control
                    
                        
                            نویسندگان
                            
                            
                        
                        
                    
                    
                    چکیده
منابع مشابه
Nasal nitric oxide is a marker of poor asthma control.
Asthma control, evaluated by symptoms, exacerbations rate and lung function may be greatly influenced by comorbidities, particularly chronic rhinosinusitis (CRS). Measurement of nasal nitric oxide (nNO) is a simple way to assess the severity of CRS. We aimed to analyze the relationship between asthma control and nasal NO. All patients with moderate-to-severe asthma on regular follow-up at our O...
متن کاملBronchodilator Response in Patients with Persistent Allergic Asthma Could Not Predict Airway Hyperresponsiveness
: Anticholinergics, or specific antimuscarinic agents, by inhibition of muscarinic receptors cause bronchodilatation, which might correlate with activation of these receptors by the muscarinic agonist methacholine. The aim of this study was to determine whether a positive bronchodilator response to the anticholinergic ipratropium bromide could predict airway hyperresponsiveness in patients with...
متن کاملUtility of bronchodilator response for asthma diagnosis in Latino preschoolers.
BACKGROUND Asthma diagnosis in preschoolers is mostly based on clinical evidence, but a bronchodilator response could be used to help confirm the diagnosis. The objective of this study is to evaluate the utility of bronchodilator response for asthma diagnosis in preschoolers by using spirometry standardised for this specific age group. METHODS A standardised spirometry was performed before an...
متن کاملBronchodilator, Terbutaline, in Asthma
subnormal responses found in patients given interriittent COT ticosteroid therapy by Malone et al. (1970). This finding, together with the satisfactory clinical response in these patients with severe disease, suggests that a therapeutic trial of depot tetracosactrin in a dose of 0-5 mg twice weekly should be considered for the control of disease requiring steroid therapy over a prolonged period...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Respiratory Medicine
سال: 2016
ISSN: 0954-6111
DOI: 10.1016/j.rmed.2016.04.017